Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Ersodetug in Tumor Hyperinsulinism (Tumor HI). The expected timing is based on the latest available company guidance and may change.
upLIFT trial. 5/5/25- Breakthrough Therapy Designation. 9/2/25- Alignment with FDA. Study initiated & enrolling patients in U.S. and Europe. Topline data in H2 2026. 01/07/26:- EAP tumor HI data show 75% discontinuing IV dextrose/TPN; upLIFT topline results still expected H2 2026. 02/12/26:- upLIFT Ph3 enrolling; topline results still expected in H2 2026. 05/12/26:- upLIFT Ph3 enrollment continues; topline tumor HI results still expected H2 2026. 06/02/26:- upLIFT 50% enrolled; 6/8 responders; topline still expected H2 2026. 06/04/26:- ENDO Jun 13 poster presents compassionate-use tumor HI case series. Topline upLIFT results still expected H2 2026. 06/17/26:- ENDO poster showed tumor HI EAP case series; interim upLIFT observations discussed; topline still expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.